Biohit Oyj 관리

관리 기준 확인 2/4

Biohit Oyj CEO는 Jussi Hahtela, Sep2022 에 임명되었습니다 의 임기는 2.17 년입니다. 는 € 92.00K 가치에 해당하는 회사 주식의 0.26% 직접 소유합니다. 92.00K. 경영진과 이사회의 평균 재임 기간은 각각 2.2 년과 5.6 년입니다.

주요 정보

Jussi Hahtela

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	2.2yrs
CEO 소유권	0.3%
경영진 평균 재임 기간	2.2yrs
이사회 평균 재임 기간	5.6yrs

최근 관리 업데이트

Recent updates

Biohit Oyj's (HEL:BIOBV) Solid Profits Have Weak Fundamentals

Feb 22

Biohit Oyj Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 17

CEO

Jussi Hahtela (51 yo)

2.2yrs

테뉴어

Mr. Jussi Hahtela serves as Chief Executive Officer of Biohit Oyj from September 02, 2022 and serves as its President. He served as Chief Financial Officer at Biohit Oyj since June 4, 2021. He is responsib...

리더십 팀

이름	위치	테뉴어	보상	소유권
Osmo Suovaniemi	Founder	36.8yrs	€14.00k	14.15% € 5.0m
Jussi Hahtela	President & CEO	2.2yrs	데이터 없음	0.26% € 92.8k
Jussi Sorvo	Chief Financial Officer	2.2yrs	데이터 없음	0.11% € 37.1k
Graham Johnson	Head of Global Sales & Marketing	less than a year	데이터 없음	데이터 없음
Yulia Kubacheva	Head of Diagnostics Department - Biohit Russia	18.4yrs	데이터 없음	데이터 없음
Ilari Patrakka	Chief Commercial Officer	less than a year	데이터 없음	0.13% € 46.7k
Panu Hendolin	R&D Director	no data	데이터 없음	0.087% € 30.6k

2.2yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 관리: BIOBV 의 관리팀은 경험 ( 2.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Osmo Suovaniemi	Founder	36.8yrs	€14.00k	14.15% € 5.0m
Vesa-Pekka Silaskivi	Independent Chairman of the Board	1.4yrs	€8.00k	데이터 없음
Mårten Wikström	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Pentti Sipponen	Scientific Advisor	no data	데이터 없음	데이터 없음
Seppo Sarna	Scientific Advisor	no data	데이터 없음	데이터 없음
Kalle Härkönen	Independent Director	2.4yrs	€14.00k	0.029% € 10.1k
Matti Harkonen	Scientific Advisor	no data	€3.00k	2.14% € 754.4k
Lea Paloheimo	Independent Director	5.6yrs	€14.00k	0.046% € 16.2k
Martti Marvola	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Feng Liu	Director	6.3yrs	€12.00k	데이터 없음

5.6yrs

평균 재임 기간

73yo

평균 연령

경험이 풍부한 이사회: BIOBV 의 이사회는 경험(평균 재직 기간 5.6 년)으로 간주됩니다.

Biohit Oyj 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Biohit Oyj Announces Changes in the Management Group

Biohit Oyj Approves Election of Vesa Silaskivi as Members of Board of Directors

Biohit Oyj Announces Executive Changes

No independent directors

Biohit Oyj Appoints Jussi Sorvo as Chief Financial Officer, Effective on September 7, 2022

Biohit Oyj Announces Executive Changes

Recent updates

First half 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 17% to €2.70

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Biohit Oyj's (HEL:BIOBV) Solid Profits Have Weak Fundamentals

Consensus EPS estimates increase by 18%

Biohit Oyj Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Full year 2023 earnings: Revenues exceed analyst expectations

Biohit Oyj to Report First Half, 2024 Results on Aug 07, 2024

Biohit Oyj Announces Changes in the Management Group

New major risk - Earnings quality

First half 2023 earnings: EPS and revenues exceed analyst expectations

Biohit Revises Earnings Guidance for 2023

Biohit Oyj Approves Election of Vesa Silaskivi as Members of Board of Directors

Full year 2022 earnings released: EPS: €0.04 (vs €0.10 loss in FY 2021)

Investor sentiment deteriorates as stock falls 19%

Biohit Oyj Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released

Biohit Oyj Announces Executive Changes

Biohit Oyj to Report Fiscal Year 2022 Final Results on Mar 22, 2023

No independent directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Biohit Oyj Appoints Jussi Sorvo as Chief Financial Officer, Effective on September 7, 2022

Biohit Oyj Announces Executive Changes

Biohit Oyj Appoints Panu Hendolin as Member of the Management Team

First half 2022 earnings released: EPS: €0.06 (vs €0.073 loss in 1H 2021)

Biohit Oyj Revises Earnings Guidance for the Year 2022

Companies Like Biohit Oyj (HEL:BIOBV) Are In A Position To Invest In Growth

Biohit Oyj Appoints Lea Paloheimo as the Chairman of the Board of Directors

Biohit Oyj Elects Kalle Härkönen as Board of Director

Less than half of directors are independent

Full year 2021 earnings: Revenues in line with analyst expectations

Biohit Oyj Provides Earnings Guidance for the Year 2022

Companies Like Biohit Oyj (HEL:BIOBV) Are In A Position To Invest In Growth

Biohit Oyj Specifies Financial Guidance for 2021

Biohit Oyj Announces Recent Clinical Validation Study Confirms the Accuracy of the New-Generation GastroPanel Test in Diagnosis of Atrophic Gastritis and Helicobacter Pylori Infection

First half 2021 earnings released: €0.073 loss per share (vs €0.15 loss in 1H 2020)

Biohit Oyj (HEL:BIOBV) Is In A Strong Position To Grow Its Business

President & CEO Semi Korpela has left the company

Biohit Oyj (HEL:BIOBV) Is In A Strong Position To Grow Its Business

Full year 2020 earnings released: €0.22 loss per share (vs €0.094 loss in FY 2019)

Full year 2020 earnings released: €0.22 loss per share (vs €0.094 loss in FY 2019)

We Think Biohit Oyj (HEL:BIOBV) Can Afford To Drive Business Growth

New 90-day high: €2.26

Biohit Oyj to Report First Half, 2021 Results on Aug 11, 2021

Biohit Oyj to Report Fiscal Year 2020 Results on Feb 17, 2021

New 90-day low: €1.99

New 90-day low: €2.00

Biohit Oyj Elects Osmo Suovaniemi as the Chairman of the Board of Directors

New 90-day low - €2.14

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령